For example, results from first-line clinical trials in advanced NSCLC patients show that compared to platinum-based chemotherapy, treatment with Pembrolizumab provides PD-L1+ patients with longer progression-free survival and overall survival, as well as fewer immune-related adverse events [138]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.